专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060178362A1 Substituted heterocyle fused gamma-carbolines 有权
标题翻译：取代的杂环稠合γ-咔啉
公开(公告)号：US20060178362A1
公开(公告)日：2006-08-10
申请号：US11375935
申请日：2006-03-15
申请人： Albert Robichaud , Taekyu Lee , Wei Deng , Ian Mitchell , Wenting Chen , Christopher McClung , Emilie Calvello , David Zawrotny
发明人： Albert Robichaud , Taekyu Lee , Wei Deng , Ian Mitchell , Wenting Chen , Christopher McClung , Emilie Calvello , David Zawrotny
IPC分类号： A61K31/538 , C07D491/14
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
摘要翻译：本发明涉及可用于治疗由结构式（I）或其药学上可接受的盐形式表示的成瘾行为和睡眠障碍的化合物，其中R 1，R 5， R 6a，R 6b，R 7，R 8，R 9， X，b，k，m和n，这里描述虚线。用于治疗本发明的方法中的化合物是血清素激动剂和拮抗剂，并且可用于控制或预防中枢神经系统疾病，包括上瘾行为和睡眠障碍。

2. 发明申请

US20060148808A1 Substituted heterocycle fused gamma-carbolines 有权
标题翻译：取代的杂环稠合的γ-咔啉
公开(公告)号：US20060148808A1
公开(公告)日：2006-07-06
申请号：US11375125
申请日：2006-03-14
申请人： Albert Robichaud , Taekyu Lee , Wei Deng , Ian Mitchell , Michael Yang , Simon Haydar , Wenting Chen , Christopher McClung , Emilie Calvello , David Zawrotny
发明人： Albert Robichaud , Taekyu Lee , Wei Deng , Ian Mitchell , Michael Yang , Simon Haydar , Wenting Chen , Christopher McClung , Emilie Calvello , David Zawrotny
IPC分类号： A61K31/498 , C07D487/14
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D471/16 , C07D487/06 , C07D491/06 , C07D495/06 , C07D513/06 , C07D513/16 , C07D519/00
摘要： The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
摘要翻译：本发明涉及可用于治疗由结构式（I）或其药学上可接受的盐形式表示的成瘾行为和睡眠障碍的化合物，其中R 1，R 5， R 6a，R 6b，R 7，R 8，R 9， X，b，k，m和n，这里描述虚线。用于治疗本发明的方法中的化合物是血清素激动剂和拮抗剂，并且可用于控制或预防中枢神经系统疾病，包括上瘾行为和睡眠障碍。

3. 发明授权

US06699852B2 Substituted pyridoindoles as serotonin agonists and antagonists 有权
标题翻译：取代的吡啶并吲哚作为血清素激动剂和拮抗剂
公开(公告)号：US06699852B2
公开(公告)日：2004-03-02
申请号：US10026611
申请日：2001-12-19
申请人： Albert Robichaud , John M. Fevig , Ian S. Mitchell , Taekyu Lee , Wenting Chen , Joseph Cacciola
发明人： Albert Robichaud , John M. Fevig , Ian S. Mitchell , Taekyu Lee , Wenting Chen , Joseph Cacciola
IPC分类号： A61K3133
CPC分类号： C07D471/16 , C07D498/16 , C07D513/16
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6, R7, R8, R9, X, b, k, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
摘要翻译：本发明涉及由结构式（I）表示的某些新化合物或其药学上可接受的盐形式，其中R 1，R 5，R 6，R 7，R 8，R <9>，X，b，k和n，这里描述虚线。本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠障碍，性障碍，偏头痛，与头痛相关的病症，社交恐怖症，以及胃肠道疾病如胃肠道运动功能障碍。

4. 发明授权

US06638934B2 Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands 有权
标题翻译：取代的吡嗪喹喔啉衍生物作为血清素受体激动剂和拮抗剂配体
公开(公告)号：US06638934B2
公开(公告)日：2003-10-28
申请号：US10026404
申请日：2001-12-19
申请人： Albert Robichaud , Ian S. Mitchell , Taekyu Lee , Wenting Chen
发明人： Albert Robichaud , Ian S. Mitchell , Taekyu Lee , Wenting Chen
IPC分类号： C07D48702
CPC分类号： C07D487/04
摘要： The present invention is directed to novel compounds represented by structural Formulas (I) and (I-a): or a pharmaceutically acceptable salt thereof, wherein R1, R4a, R4b, R5, R6, R7, R8, R9, n, and X are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep and sexual disorders, migraine and other conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
摘要翻译：本发明涉及由结构式（I）和（Ia）表示的新化合物：或其药学上可接受的盐，其中R 1，R 4a，R 4b，R 5， R 6，R 7，R 8，R 9，n和X如本文所述。本发明还涉及包含这些新化合物作为活性成分的药物制剂，以及新型化合物及其制剂在治疗某些疾病中的用途。本发明的化合物是血清素激动剂和拮抗剂，可用于控制或预防中枢神经系统疾病，包括肥胖症，焦虑症，抑郁症，精神病，精神分裂症，睡眠和性障碍，偏头痛和与头痛相关的其他病症，社交恐怖症，以及胃肠道疾病如胃肠道运动功能障碍。

5. 发明授权

US06548493B1 Substituted heterocycle fused gamma-carbolines 有权
公开(公告)号：US06548493B1
公开(公告)日：2003-04-15
申请号：US09594008
申请日：2000-06-15
申请人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. B. Calvello , David M. Zawrotny
发明人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. B. Calvello , David M. Zawrotny
IPC分类号： C07D51316
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

6. 再颁专利

USRE39679E1 Substituted heterocycle fused gamma-carbolines 有权
公开(公告)号：USRE39679E1
公开(公告)日：2007-06-05
申请号：US11356423
申请日：2006-02-16
申请人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emile J. B. Calvello , David M. Zawrotny , Parthasarathl Rajagopalan
发明人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Michael Guang Yang , Simon Haydar , Wenting Chen , Christopher D. McClung , Emile J. B. Calvello , David M. Zawrotny , Parthasarathl Rajagopalan
IPC分类号： C07D267/22 , C07D281/18 , C07D267/02 , C07D279/00 , C07D265/34
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.

7. 发明申请

US20050239768A1 Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists 有权
标题翻译：取代的六氢 - 吡啶并吲哚衍生物作为血清素受体激动剂和拮抗剂
公开(公告)号：US20050239768A1
公开(公告)日：2005-10-27
申请号：US11104933
申请日：2005-04-13
申请人： Taekyu Lee , Wei Deng , Albert Robichaud
发明人： Taekyu Lee , Wei Deng , Albert Robichaud
IPC分类号： A61K31/435 , A61K31/437 , A61K31/4745 , A61K31/55 , A61P3/04 , A61P25/00 , C07D471/02 , C07D471/04 , C07D487/02 , C07D487/04
CPC分类号： C07D471/04
摘要： The present application provides novel compounds according to Formula (I): including all stereoisomers, solvates, prodrug esters and pharmaceutically acceptable salt forms thereof, wherein R1, R4a, R5, R6, R7, R8, R9, m, and X are described herein. Additionally, the present application provides novel pharmaceutical compositions comprising at least one compound according to Formula (I). Further, the present application provides methods of treating a patient in need comprising administering a therapeutically effective amount of at least one compound according to Formula (I).
摘要翻译：本申请提供了根据式（I）的新化合物：包括所有立体异构体，溶剂合物，前药酯及其药学上可接受的盐形式，其中R 1，R 4，R 4，R R 5，R 6，R 7，R 8，R 9，M 9，，和X。另外，本申请提供了包含至少一种根据式（I）的化合物的新型药物组合物。此外，本申请提供了治疗需要的患者的方法，其包括施用治疗有效量的至少一种根据式（I）的化合物。

8. 发明授权

US07238690B2 Substituted heterocycle fused gamma-carbolines 有权
标题翻译：取代的杂环稠合的γ-咔啉
公开(公告)号：US07238690B2
公开(公告)日：2007-07-03
申请号：US11375935
申请日：2006-03-15
申请人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. Calvello , David M. Zawrotny
发明人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. Calvello , David M. Zawrotny
IPC分类号： C07D491/16 , A61K31/5383
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to compounds useful for treating addictive behavior and sleep disorders represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
摘要翻译：本发明涉及可用于治疗由结构式（I）或其药学上可接受的盐形式表示的成瘾行为和睡眠障碍的化合物，其中R 1，R 5， R 6a，R 6b，R 7，R 8，R 9， X，b，k，m和n，这里描述虚线。用于治疗本发明的方法中的化合物是血清素激动剂和拮抗剂，并且可用于控制或预防中枢神经系统疾病，包括上瘾行为和睡眠障碍。

9. 发明授权

US07109339B2 Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists 有权
标题翻译：取代三环γ-咔啉作为血清素受体激动剂和拮抗剂
公开(公告)号：US07109339B2
公开(公告)日：2006-09-19
申请号：US10743449
申请日：2003-12-19
申请人： Taekyu Lee , Wenting Chen , Wei Deng , Albert J. Robichaud , Ruth R. Wexler
发明人： Taekyu Lee , Wenting Chen , Wei Deng , Albert J. Robichaud , Ruth R. Wexler
IPC分类号： C07D417/00 , C07D471/04
CPC分类号： C07D471/04
摘要： The present invention is directed to novel compounds represented by structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R4a, R5, R6, R7, R8, R9,and m, are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain central nervous system disorders. The compounds of this invention are serotonin receptor modulators, in particular 5HT2C receptor agonists and antagonists, and are useful in the control or prevention of central nervous system disorders including obesity, anorexia, bulemia, depression, anxiety, psychosis, schizophrenia, migraine, addictive behavior, obsessive-compulsive disorder, and sexual disorders.
摘要翻译：本发明涉及由结构式（I）表示的新化合物或其药学上可接受的盐，其中R 1，R 4a，R 5， R 6，R 6，R 7，R 8，R 9和M如本文所定义。本发明还涉及包含这些新化合物作为活性成分的药物制剂以及新型化合物及其制剂在治疗某些中枢神经系统疾病中的用途。本发明的化合物是5-羟色胺受体调节剂，特别是5HT 2C受体激动剂和拮抗剂，并且可用于控制或预防中枢神经系统疾病，包括肥胖症，厌食症，血症，抑郁症，焦虑症，精神病，精神分裂症，偏头痛，成瘾行为，强迫症和性功能障碍。

10. 发明授权

US07081455B2 Substituted heterocycle fused gamma-carbolines 有权
标题翻译：取代的杂环稠合的γ-咔啉
公开(公告)号：US07081455B2
公开(公告)日：2006-07-25
申请号：US10786935
申请日：2004-02-25
申请人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. Calvello , David M. Zawrotny
发明人： Albert J. Robichaud , Taekyu Lee , Wei Deng , Ian S. Mitchell , Wenting Chen , Christopher D. McClung , Emilie J. Calvello , David M. Zawrotny
IPC分类号： A61P25/00
CPC分类号： C07D471/06 , C07D221/18 , C07D223/32 , C07D491/06 , C07D495/06
摘要： The present invention is directed to methods of treating addictive behavior and sleep disorders by administering compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The compounds used in the method of treatment of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including addictive behavior and sleep disorders.
摘要翻译：本发明涉及通过施用由结构式（I）表示的化合物或其药学上可接受的盐形式来治疗成瘾行为和睡眠障碍的方法，其中R 1，R 5， R 6a，R 6b，R 7，R 8，R 9，R 9， >，X，b，k，m和n，这里描述虚线。用于治疗本发明的方法中的化合物是血清素激动剂和拮抗剂，并且可用于控制或预防中枢神经系统疾病，包括上瘾行为和睡眠障碍。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式